New Alpha Innovation

New Alpha Innovation (NAI) is a biopharmaceutical company specializing in the development of hemoglobin-based oxygen carriers (HBOCs) for both human and veterinary medicine. The company's portfolio includes products like Oxapex and Oxamex, which are approved in various regions for treating anemia and hemorrhagic shock in animals, as well as YQ23, a human therapeutic being evaluated for solid tumors and critical limb ischemia. NAI utilizes a proprietary platform to create artificial hemoglobin solutions that effectively deliver oxygen to tissues and organs. In early 2024, the company's HBOC project and associated global intellectual property were acquired by BIOS Biotechnology Co., Ltd., positioning the combined entity as a leader in the artificial hemoglobin sector.